Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Vicarious Surgical Inc. (RBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RBOT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -18.47% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.59M USD | Price to earnings Ratio - | 1Y Target Price 10.75 |
Price to earnings Ratio - | 1Y Target Price 10.75 | ||
Volume (30-day avg) 33137 | Beta 1.36 | 52 Weeks Range 4.27 - 19.00 | Updated Date 04/1/2025 |
52 Weeks Range 4.27 - 19.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.42 |
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -2.69 | Actual -2.43 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.35% | Return on Equity (TTM) -87.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3592748 | Price to Sales(TTM) - |
Enterprise Value 3592748 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.41 | Shares Outstanding 5276610 | Shares Floating 3734500 |
Shares Outstanding 5276610 | Shares Floating 3734500 | ||
Percent Insiders 26.35 | Percent Institutions 34.11 |
Analyst Ratings
Rating 3.67 | Target Price 11.75 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vicarious Surgical Inc.
Company Overview
History and Background
Vicarious Surgical Inc. was founded in 2014. It focuses on developing minimally invasive surgical robots with enhanced visualization and dexterity. They went public via SPAC in 2021.
Core Business Areas
- Robotic Surgery Systems: Develops and commercializes robotic surgical systems designed to improve minimally invasive procedures.
- Surgical Tools and Accessories: Offers specialized tools and accessories compatible with its robotic surgical platform.
- Software and Visualization: Provides advanced software and visualization capabilities to enhance surgical precision and outcomes.
Leadership and Structure
Adam Sachs (CEO), co-founded the company. The company has a typical corporate structure with executive leadership in engineering, operations, and finance.
Top Products and Market Share
Key Offerings
- Vicarious Surgical System: Their main product is a surgical robot system designed for minimally invasive surgery. As the product is still in development and not commercially available, there is no significant market share. Competitors include Intuitive Surgical (ISRG) with its da Vinci system and Medtronic (MDT) with its Hugo system.
Market Dynamics
Industry Overview
The surgical robotics market is growing due to increasing demand for minimally invasive procedures, technological advancements, and an aging population.
Positioning
Vicarious Surgical aims to differentiate itself through its focus on human-like dexterity and enhanced visualization in minimally invasive surgery.
Total Addressable Market (TAM)
The total addressable market for surgical robots is estimated to be in the tens of billions of dollars. Vicarious Surgical is positioned to capture a portion of this market pending successful commercialization and adoption.
Upturn SWOT Analysis
Strengths
- Innovative Technology
- Strong Intellectual Property
- Experienced Management Team
- Focus on Minimally Invasive Surgery
Weaknesses
- Pre-revenue Status
- High R&D Costs
- Regulatory Hurdles
- Dependence on Future Funding
Opportunities
- Expanding Surgical Robotics Market
- Strategic Partnerships
- Technological Advancements
- Increasing Adoption of Minimally Invasive Procedures
Threats
- Competition from Established Players
- Technological Obsolescence
- Economic Downturn
- Regulatory Changes
Competitors and Market Share
Key Competitors
- ISRG
- MDT
- SIFI
Competitive Landscape
Vicarious Surgical faces intense competition from established players with proven products and extensive market presence. They need to overcome a lot of hurdles
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as the company is pre-revenue.
Future Projections: Future growth depends on successful product development, regulatory approvals, and commercialization. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include continued development of the Vicarious Surgical System, preclinical studies, and regulatory submissions.
Summary
Vicarious Surgical is a pre-revenue company with innovative technology in surgical robotics, but it faces challenges in funding, competition, and regulatory approvals. The company's success hinges on the successful commercialization of its robotic system. It needs to secure further funding to avoid cash flow issues. Successful regulatory pathways will be crucial.
Similar Companies
- ISRG
- MDT
- SIFI
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The surgical robotics market is dynamic and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vicarious Surgical Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-04 | Co-Founder, CEO & Director Mr. Adam David Sachs | ||
Sector Healthcare | Industry Medical Devices | Full time employees 123 | |
Full time employees 123 | |||
Vicarious Surgical Inc. develops and sells single-port surgical robot in the United States. It offers Vicarious Surgical System, a single-port surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.